title: Diabetes tolerogenic vaccines targeting antigen-specific inflammation.
abstract: Tolerance controls the magnitude of inflammation, and balance between beneficial and harmful effects of inflammation is crucial for organ function and survival. Inadequate tolerance leads to various inflammatory diseases. Antigen specific tolerance is ideal for inflammation control as alternative anti-inflammatory interventions are non-specific and consequently increase the risk of infection and tumorigenesis. With inherent antigen specificity, tolerogenic vaccines are potentially ideal for control of inflammation. Although the concept of tolerogenic vaccines is still in its infancy, tolerogenic mucosal vaccines and specific immuno-therapies have long been proven effective in pioneering examples. Now a body of evidence supporting the concept of tolerogenic vaccines has also accumulated. Here we comment on recent successes of the tolerogenic vaccine concept, present new evidence with a type 1 diabetes vaccine as an example and draw conclusions on the advantages and potential for inflammatory disease control at the bedside.
authors.affiliation: a Key Laboratory of Medical Molecular Virology of MOH and MOE ; Fudan University Shanghai Medical College ; Shanghai , China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Geng
authors.forename: Huiyuan
authors.initials: H
authors.lastname: Zhang
authors.forename: Xian
authors.initials: X
authors.lastname: Zhou
authors.forename: Yue
authors.initials: Y
authors.lastname: He
authors.forename: Xiaoqian
authors.initials: X
authors.lastname: Zhang
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Xie
authors.forename: Chaofan
authors.initials: C
authors.lastname: Li
authors.forename: Zhonghuai
authors.initials: Z
authors.lastname: He
authors.forename: Qingling
authors.initials: Q
authors.lastname: Yu
authors.forename: Yiwei
authors.initials: Y
authors.lastname: Zhong
authors.forename: Douglas B
authors.initials: DB
authors.lastname: Lowrie
authors.forename: Guoxing
authors.initials: G
authors.lastname: Zheng
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D014612:Vaccines / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D014612:Vaccines
keywords: antigen specific inhibition; autoimmune disease treatment; co-immunization; immune suppression; immuno-suppressors; inflammation; suppressive vaccine; tolerance; tolerogenic vaccine; type 1 diabetes